Objective: Low HDL-C and HDL particle size may directly promote hyperglycemia. We evaluated associations of HDL-C, apoA-I, and HDL-C/apoA-I with insulin secretion, insulin resistance, HbA1c and long-term glycemic deterioration, reflected by initiation of pharmacologic glucose control.
Introduction
Type 2 diabetes is a progressive disease, characterized by insulin resistance and ongoing loss of endogenous insulin secretion with increased requirement for pharmacologic glucose control over time (1, 2) . Low HDL cholesterol (HDL-C) is a common finding in type 2 diabetes patients and is best known as a predictor of cardiovascular risk (3) (4) (5) . Furthermore changes to HDL-C levels, HDL particles and their major apolipoprotein, apoA-I, are reported to be present years before the development of type 2 diabetes (6) (7) (8) (9) (10) (11) (12) . This raises the question of whether HDL biology contributes directly to the development of type 2 diabetes and the continuing progression of the disease.
Associations between HDL related measures and incident type 2 diabetes may reflect comorbid conditions such as hypertriglyceridemia, abdominal obesity and insulin resistance, which also portend incident disease. However, recent pre-clinical evidence suggests that the action of HDL particles and apoA-I can independently promote insulin secretion and glucose uptake in patients with type 2 diabetes (13, 14) . Human islet-cell culture and animal studies have reported that exogenous HDL improves insulin secretion through increased reverse cholesterol transport and attenuation of LDL and inflammation-induced apoptosis of pancreatic beta-cells (13, 15) . HDL and apoA-I may also promote glucose uptake by skeletal muscle through activating the AMPK pathway (16) . In humans with type 2 diabetes, measures of endogenous HDL function have been inversely associated with concurrent estimated beta-cell function (17) . Also, infusion of exogenous reconstituted HDL over 4 hours increased both insulin secretion and skeletal muscle glucose uptake in a small trial with type 2 diabetes patients (18) . Cross-sectional studies have reported an inverse association between HbA1c and HDL-C in type 2 diabetes (19, 20) . Further, a number of studies have linked HDL-C levels to the development of incident type 2 diabetes (6) (7) (8) 10) . However, to date, no study has examined the relationship between these biomarkers and the progression of established diabetes.
The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial was a randomized controlled trial of fenofibrate therapy in 9795 adult type 2 diabetes patients, with measures of HDL-C and apoA-I at baseline. We investigated the whether HDL-C, apoA-I and HDL particle size, as estimated by the HDL-C/apoA-I ratio (21) , were inversely associated both cross-sectional measures of glycemia and prospectively with requirements for escalation of glucose control therapies, which would be consistent with HDL having antidiabetic effects. We also considered associations of the HDL-related measures with two key determinants of glycemia, pancreatic beta-cell secretion and insulin resistance.
Research Design and Methods

Subjects
The FIELD study design has been published previously (22, 23) . All participants had an initial total plasma cholesterol of 3.0-6.5 mmol/L, plus a total cholesterol to HDL-C ratio of 4.0 or higher, or a fasting plasma triglyceride reading of 1.0-5.0 mmol/L. The study excluded those who had an existing indication for lipid modifying therapy, renal impairment (plasma creatinine ≥ 130 micromol/L), chronic liver disease (alanine aminotransferase (ALT) ≥ 2 times the upper limit of normal), symptomatic gallbladder disease, or those who had experienced a cardiovascular event within the 3 months before recruitment. Patients were followed up every 4 months in the first year and then every 6 months for a median of 5 years.
Measurements and outcomes
Fasting serum HDL-C, serum apoA-I, plasma glucose, serum insulin and HbA1c were measured at baseline in two core laboratories aligned to the Canadian Reference Laboratory.
We then calculated the HDL-C/apoA-I ratio. In subjects not taking exogenous insulin (n=8271), Homeostasis Model Assessment (v2.2.2, 12 December 2007; www.dtu.ox.ac.uk) was used to derive estimates of pancreatic β-cell secretion (HOMA-B) and insulin resistance (HOMA-IR) from fasting plasma glucose and serum insulin (24) . As recommended by the model's authors, HOMA calculations were further limited to patients with glucose readings between 3 and 25 mmol and insulin levels between 20 and 400 pmol (25). Medications were recorded at each visit. Baseline adiposity was assessed using BMI, waist circumference and waist to hip ratio. Renal function was assessed using both estimated GFR and the presence of albuminuria. Evidence of fatty liver change was inferred from alanine aminotransferase (ALT) readings. Self-reported smoking status, regular alcohol consumption and physical exercise were recorded at baseline. At all centers, changes in medication use were recorded at baseline and at each subsequent visit by a qualified clinical trials nurse using a common drug dictionary which was later converted to ATC code. For patients commencing the trial on lifestyle measures alone, we regarded initiation of oral hypoglycemic agents or insulin therapy by the patients' usual general practitioner or endocrinologist, once confirmed, as evidence of escalation of diabetes therapy.
Statistical analysis
We first considered age and sex-adjusted partial correlations between baseline variables, which were logarithmically transformed as appropriate. Partial correlations with HOMA-B were additionally adjusted for HOMA-IR. Linear regression analysis was used in order to further adjust for possible confounders, which were selected based on known or suspected association with the variables of interest. All baseline analyses were repeated in the lifestyle only sub-group (n = 2608) to avoid possible confounding effects of OHAs or insulin therapy.
In the same sub-group, we used Cox proportional hazards models to consider whether lower HDL-C, apoA-I or HDL-C/apoA-I was associated with more rapid uptake of OHAs and insulin therapy during follow up. Interaction terms for treatment allocation were evaluated.
Models were adjusted for HOMA-IR, BMI and HbA1c, triglycerides, waist circumference, hypertension, LDL-C, ALT, eGFR, the presence of albuminuria, current smoking, regular alcohol consumption, physical exercise and menopause status in women. In separate timedependent Cox regression analyses we evaluated the effect of uptake of statins and angiotensin converting enzyme inhibitors (ACEi) / angiotensin receptor blockers (ARBs) during follow-up. Where a HDL-related measure was found to be a significant predictor of progression to pharmacologic glucose control, we aimed to exclude possible interactions between the measure and glycemic management. We classed participants into sex-stratified quartiles according to each relevant measure. Using a one-way ANOVA, we assessed whether the highest quartile of the measure was associated with a greater rise in HbA1c than the lowest quartile. In those who initiated pharmacologic glucose control, we compared the last recorded HbA1c before therapeutic progression between the highest and lowest quartiles of a measure, using a Kruskal-Wallis test. P-values are presented unadjusted for multiple comparisons. All analyses used SPSS 20.0 (IBM Corp., Armonk, NY) or SAS 9.1 software (SAS Institute Inc., Cary, NC).
Results
The 9795 FIELD participants had a mean age of 62±7 years with a median diabetes duration Baseline characteristics for the entire cohort as well as for subgroups on hypoglycemic pharmacotherapy and on lifestyle-measures only are presented in Table 1 .
Baseline age and sex adjusted partial correlations are shown in Table 2 . There were no significant partial correlations of HDL-C, apoA-I or HDL-C/apoA-I with HbA1c in the whole cohort (n=9795) or in the lifestyle only subset (n=2608). This persisted after additional adjustment, by linear regression, for possible confounders, which were duration of diabetes, 
Conclusions
In our large study of predominantly Caucasian subjects with established type 2 diabetes we report the novel observation that lower levels of HDL-C and a lower HDL-C/apoA-I ratio predict substantially earlier initiation of pharmacologic glucose control among those initially treated with lifestyle measures alone. This is in spite of no statistically significant baseline cross-sectional associations between HDL-related measures and HbA1c levels. The inverse association of progression to pharmacologic glucose control with HDL-C/apoA-I, which estimates HDL size, persists after adjustment for multiple metabolic and lifestyle factors. The results are thus consistent with the emerging concept that HDL biology may play a direct role in the development and progression of type 2 diabetes.
Our prospective findings need to be considered in light of our cross-sectional analysis which did not find hypothesized associations of HDL-C, apoA-I or HDL-C/apoA-I with HbA1c or HOMA-B. There was no inverse correlation between HbA1c levels and HDL-related measures, despite low HDL-C being more common in type 2 diabetes patients than in the general population (3) . Two smaller studies of type 2 diabetes patients in Italy and Saudi Arabia have previously reported modest but statistically significant inverse associations between HDL-C and HbA1c (r=-0.183, p<0.05, r = -0.074, p<0.005 respectively) (19, 20) . In both studies, participants appeared to have higher average HbA1c and HDL-C levels and longer diabetes duration than subjects in our study. Although our cohort is typical of an early type 2 diabetes population it was selected for the purposes of a clinical trial. Lipid values formed part of the selection criteria and thus may have limited variability in HDL-C at baseline. Among all subjects who were screened for the trial (n=13900; HDL-C range 0.29- It considered 705 patients who had an HbA1c≤7% [HbA1c≤53mmol/mol] and were using lifestyle measures alone at baseline (29) . In unadjusted analyses, baseline HDL-C levels were lower amongst those who progressed to OHAs or whose HbA1c levels rose above 7% at the end of one-year.
Similarly, we have used the progression from lifestyle measures to pharmacologic glucose lowering as an index of worsening glycemia. During the trial, HbA1c below 7.0%
[53mmol/mol] was the accepted target and first OHAs were instituted at a median HbA1c of 7.1% [54mmol/mol] in FIELD subjects (23, 30). Nevertheless, the study protocol did not dictate glycemic management hence the possibility would exist that an association between low baseline HDL-C levels and initiation of first glycemic therapy might reflect more aggressive prescribing related to perceived low HDL-C mediated risk. In order to exclude this possibility, we examined whether baseline HDL-C (or HDL-C/apoA-I) levels influenced either the HbA1c levels at which pharmacotherapy was commenced or total HbA1c rises over 5 years. Neither analysis supported such an alternative explanation. Also, lower baseline HDL-C and HDL-C/apoA-I predicted both earlier metformin and sulphonylurea uptake suggesting that our results were independent of the mode of pharmacotherapy employed (results not shown).
Our longitudinal analysis is adjusted for multiple lifestyle and metabolic factors, which could influence relationships between HDL-related measures and type 2 diabetes progression. Low physical activity, alcohol non-consumption and smoking are lifestyle factors that are associated with lower HDL-C and multiple other metabolic alterations (31, 32) . These factors did not materially affect the predictive value of HDL-C or HDL-C/apoA-I in our cohort.
Similarly, the Prevention of Renal and Cardiovascular End-Stage Disease (PREVEND) study recently reported that both HDL-C and HDL-C/apoA-I predicted incident type 2 diabetes independently of current smoking and alcohol consumption (8) . In the Diabetes Prevention
Program (DPP), on-study HDL-C rise was associated with less progression to type 2 diabetes in the intensive lifestyle, metformin and control arms (28) .
In contrast to lifestyle factors, metabolic factors, in FIELD, partially account for the observed relationship between HDL-related measures and pharmacologic glucose control initiation.
After controlling for HOMA-IR and triglycerides, the hazard ratios for both HDL-C and HDL-C/apoA-I were attenuated and only HDL-C/apoA-I remained a significant predictor of progression to OHAs or insulin. Elevated insulin resistance and triglycerides are both independently and inversely associated with reduced HDL-C and HDL/apoA-I (33). Both factors are also thought to promote islet cell stress and apoptosis via associations with systemic low grade inflammation and increased free fatty acid levels (27, 34, 35) . Higher triglyceride levels and larger VLDL particles have also been reported to predict incident type 2 diabetes (9, 10). However studies diverge as to whether HDL-related or triglyceride-related measures are stronger predictors of incident disease. Importantly, the PREVEND study recently reported that both HDL-C and HDL-C/apoA-I predicted incident type 2 diabetes independent of triglyceride levels or HOMA-IR (8).
Our study thus provides further support for the notion that smaller cholesterol-poor HDL particles, reflected by lower HDL-C levels and HDL-C/apoA-I ratios, may contribute directly to worsening glycemia. Alteration to HDL size and cholesterol content may reflect reduced efficacy of reverse cholesterol transport in type 2 diabetes (36, 37). Since HDL-mediated reverse cholesterol transport has been positively associated with insulin secretion and broader anti-inflammatory effects, this could provide a link between a reduced HDL/apoA-I ratio and more rapid deterioration in glycemic control (14, 18, 38) .
Strengths of our study include a large sample size, and the ability to account for multiple possible confounders, including lifestyle factors, metabolic factors and statin and ACEi/ARB use. The length of follow-up and the high rate of therapy initiation enabled us to derive median times to event, which has not been possible in studies of diabetes incidence. The study has some limitations. Caucasian ethnicity was reported by 93% of subjects, which may limit the generalizability of the results. Lifestyle factors, which can influence HDL metabolism, were self-reported and may be affected by under-reporting. Unless underreporting was differential with respect to HDL, this would only increase random error rather than introducing bias. Recording of escalation of diabetes therapy could contain inaccuracies, however any possible misclassification would result in dilution of potential associations with HDL-related parameters, rather than the converse. This sub-study was not a stated purpose of the FIELD trial, however all analyses were performed after a hypothesis and pre-specified analysis plan were prepared. One of the FIELD inclusion criteria was a total-cholesterol-to-HDL-C ratio greater than 4. This may have some bearing on the range and spread of HDLrelated measures in our cross-sectional analysis but, if anything, would have lead us to underestimate our significant longitudinal associations. HOMA model estimates are not as reliable as those using clamp methods, and could not be carried out on all subjects. However they are a useful proxy in the context of a large cohort (39) . HDL function and size were not directly measured in this study and HDL-C and apoA-I may not reflect HDL function well (14, 17, 37) . However HDL-C is the most studied HDL-related measure and is predictive of cardiovascular and microvascular complications in type 2 diabetes (4, 5, 40) . ApoA-I is widely available, and elucidating its predictive value in type 2 diabetes is important. The HDL-C/apoA-I ratio is easy to derive, reasonably approximates HDL particle size, and has been previously linked to incident type 2 diabetes (8, 21) . Nonetheless, large clinical studies evaluating the associations of HDL particle number and function with concurrent and long term glycemia in established type 2 diabetes would be of interest.
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In summary, lower levels of baseline HDL-C and HDL-C/apoA-I were not cross-sectionally associated with HbA1c, but predicted earlier initiation of pharmacologic glucose control over 5 years in people with pre-existing type 2 diabetes. In particular, the value of HDL-C/apoA-I, an estimate of HDL particle size, in predicting glycemic progression, was independent of all measured confounders. This provides clinical support for a direct involvement of HDL biology in worsening glycemia in people with established type 2 diabetes. HbA1c, HOMA-IR and HOMA-B were logarithmically transformed prior to correlation and regression analyses as described in the methods section. . a . correlation is significant at the 0.05 level (2-tailed) . Hazard ratios and 95% confidence intervals for uptake of pharmacologic glucose therapyresults are displayed as the effect of 1 standard deviation (SD) lower baseline value of (A) HDL-C and (B) HDL-C/apoA-I respectively. Results are cumulatively adjusted for age and sex, then HOMA-IR, BMI, HbA1c, Triglyceride levels, and lastly also for the potential confounders of LDL-C, waist circumference, hypertension, ALT, eGFR, the presence of micro or macroalbuminuria, female menopause status, current smoking, regular alcohol consumption and physical exercise.
Author Declarations
